llumina on Thursday forecast core business revenue to be nearly flat in the coming year compared to 2023 amid subdued demand for its genetic testing tools and diagnostics products. The San Diego-based ...

Bangalore (Reuters) - Companies that make the gene-sequencing devices used in scientific research face a tough few years as potential cuts to the U.S. federal budget squeeze funding to its main ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...

The ban, which has been in place since March 4 following President Trump's doubling of tariffs on China, is expected to be ...

Illumina Inc. introduced a new line of gene-sequencing machines that the company says can more than double capacity versus prior sequencers, while reducing the cost per genome. The rollout, which ...

Illumina (NASDAQ:ILMN) on Monday lowered its adjusted profit outlook and cut spending costs for 2025 as the company grapples with a Chinese ban on its gene sequencers. Illumina now expects fiscal 2025 ...

Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader. Bionano Genomics is unproven but expanding quickly. So ...

SANTA CLARA, CA--(Marketwire - Oct 31, 2012) - NVIDIA® Tesla® GPU accelerators are enabling Life Technologies Corporation's new Ion Proton™ System to accelerate primary genome-sequence analysis-- the ...

Illumina's shares are getting rocked by a handful of serious but short-term problems. Its share of the global gene sequencer market isn't eroding, nor is its brand value. Once it gets through the ...

Companies like Ultima Genomics say they have the technology, which could lead to medical breakthroughs. But similar promises in the past have fizzled and barriers remain. By Roy Furchgott This article ...